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Background:  There is a need of effective non-invasive biomarkers for diagnosis and prognosis of the syndrome of heart failure (HF). A 
characteristic odor exhaled by hospitalized patients with acute decompensated heart failure (ADHF) was observed clinically and chemically 
investigated by the authors. 
Methods: The following number of ADHF patients admitted to the Emergency Department and stable HF patients treated at Outpatients fulfilled 
the selection rules of the study, divided according to their hemodynamic profile: 13 of group 3 - congestive heart failure, CongHF; 11 of group 4 - 
low output heart failure, LOHF; 17 of group 2 - stable, compensated heart failure, CompHF; additionally, 20 healthy volunteers of group 1 - control, 
sorted by age (average age of 50.0±12). Diabetics were excluded. Breath samples were analyzed by collection in impingers (extraction into water), 
identification by chromatography-mass spectrometry (GC-MS) and routine determination by spectrophotometry after reaction with salicylaldehyde. 
The statistic analysis was done using the non-parametric test of Kruskal Wallis. 
Results:  The principal exhaled breath air substance responsible for the characteristic odor was the acetone. Median concentration of acetone 
was significantly higher (p<0.001) in CongHF group (7.1mcg/l [range, 0.9-20]) and LOHF group (7.1mcg/l [1.6-45]) in relation to the CompHF 
(1.3mcg/l [0.1-2.8]) and controls (0.4 mcg/l [0.0-1.1]). Initial results point out that acetone concentration in exhaled air of patients with HF 
correlates with the severity of the disease, since concentrations greater than 2.6 mcg/L indicated sensitivity of 88% and specificity of 88% for 
diagnosing ADHF with diagnostic accuracy of 88%, regardless of the type of decompensation, be it by congestion or by low output. There was also 
a positive correlation between the concentrations of acetone and BNP (r= 0.716, p<0.001). Moreover, the collection method of the proposed 
biomarker has the advantage of being non-invasive. 
Conclusions:  Exhaled acetone in patients with HF is a new and promising non-invasive method of diagnosis of HF in non-diabetic individuals, 
especially those at high risk, and deserves further research.
